Article
Neurosciences
Waijiao Cai, Kazumasa Wakamatsu, Fabio A. Zucca, Qing Wang, Kai Yang, Niyaz Mohamadzadehonarvar, Pranay Srivastava, Hitomi Tanaka, Gabriel Holly, Luigi Casella, Shosuke Ito, Luigi Zecca, Xiqun Chen
Summary: By studying samples of substantia nigra from patients with Parkinson's disease, we found increased ratios of pheomelanin to dopamine in the melanin content, as well as reduced levels of eumelanins derived from both DOPA and dopamine. Additionally, an increase in pheomelanin relative to dopamine pheomelanin was observed in Parkinson's disease. These findings provide insights into the roles of pheomelanin and eumelanin in the pathophysiology of Parkinson's disease.
PROGRESS IN NEUROBIOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Kathryn Lanza, Christopher Bishop
Summary: Parkinson's Disease (PD) and long-term L-DOPA treatment induce plasticity that contributes to L-DOPA-induced dyskinesia (LID), with the dopamine D3 receptor (D3R) emerging as a promising target in LID management due to its upregulation in LID. D3R undergoes dynamic changes in both PD and LID, and recent genetic and pharmacologic tools have helped clarify its role in LID.
Article
Clinical Neurology
Tomi Kuusimaki, Haidar Al-Abdulrasul, Samu Kurki, Jarmo Hietala, Sirpa Hartikainen, Marjaana Koponen, Anna-Maija Tolppanen, Valtteri Kaasinen
Summary: The study revealed that schizophrenia spectrum disorder increases the risk of developing Parkinson's disease, as observed in both individual patient data and nationwide register data.
MOVEMENT DISORDERS
(2021)
Article
Biochemistry & Molecular Biology
Vladimir M. Pogorelov, Michael L. Martini, Jian Jin, William C. Wetsel, Marc G. Caron
Summary: L-DOPA is the main treatment for Parkinson's disease, but it can lead to dyskinesia over time. In this study, dopamine-depleted dopamine-transporter KO (DDD) mice were used as an acute PD model to screen novel compounds for anti-parkinsonian and L-DOPA-induced dyskinesia. The researchers found that oral stereotypies could be used as an index for LID in DDD mice.
Article
Biochemistry & Molecular Biology
Piyong Sola, Praveen Thaggikuppe Krishnamurthy, Mamta Kumari, Gowramma Byran, Hosahalli Veerabhadrappa Gangadharappa, Kusuma Kumari Garikapati
Summary: Neurodegeneration is a significant threat in Parkinson's disease and is responsible for both motor and non-motor symptoms. Current treatments aim to increase dopamine levels but have limited effectiveness in halting disease progression. Therefore, the development of neuroprotective agents is necessary for better management of Parkinson's disease.
NEUROCHEMISTRY INTERNATIONAL
(2022)
Article
Clinical Neurology
Yulu Song, Tao Gong, Yuanyuan Xiang, Mark Mikkelsen, Guangbin Wang, Richard A. E. Edden
Summary: This preliminary study found that GABA+ levels in the upper brainstem were significantly increased in PD patients post-L-dopa administration, suggesting that dopaminergic therapy may improve GABA+ levels in the upper brainstem and modulate the GABAergic system in the treatment of PD.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2021)
Article
Neurosciences
Keita Sugiyama, Mahomi Kuroiwa, Takahide Shuto, Yoshinori N. Ohnishi, Yukie Kawahara, Yuta Miyamoto, Takaichi Fukuda, Akinori Nishi
Summary: The striatum, the main structure of the basal ganglia, is subdivided into seven subregions with distinct roles in motor and emotional functions. Dopamine D1 receptor signaling is region-specifically regulated in the striatum, with aberrant activation in the IC associated with L-DOPA-induced dyskinesia. Future research focusing on D1 receptor signaling in the IC may lead to novel therapeutics for LID.
JOURNAL OF NEUROSCIENCE
(2021)
Article
Chemistry, Analytical
Chia-Wen Chang, Yu-Hsuan Lin, Cheng-Han Tsai, Sivasankar Kulandaivel, Yi-Chun Yeh
Summary: A novel heat-stable enzyme was developed for a protein-and cell-based biosensor, enabling the detection of L-DOPA for the first time. The detection of L-DOPA was achieved through a red fluorescent signal within 30 minutes. Furthermore, a sequential analysis method using dual-fluorescent signals was developed for the sensitive detection of dopamine and L-DOPA coexistence, allowing for monitoring of the therapy for Parkinson's disease patients treated with L-DOPA.
ANALYTICA CHIMICA ACTA
(2022)
Article
Biochemistry & Molecular Biology
Osama F. Elabi, Jeffrey S. Davies, Emma L. Lane
Summary: GLP-1R agonists can increase graft survival and improve motor function in rats to a certain extent. However, there are differences in effects between different treatment groups that need further investigation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Luca Magistrelli, Marco Ferrari, Alessia Furgiuele, Anna Vera Milner, Elena Contaldi, Cristoforo Comi, Marco Cosentino, Franca Marino
Summary: Parkinson's disease is a neurodegenerative disorder caused by loss of dopaminergic neurons. Treatment relies on dopaminergic replacement, but genetic factors can influence the clinical progression and drug response in patients. Understanding the genetic variability of dopaminergic receptors may provide insights into the development of personalized therapies for PD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Tung-Tai Kuo, Yuan-Hao Chen, Vicki Wang, Eagle Yi-Kung Huang, Kuo-Hsing Ma, Nigel H. H. Greig, Jin Jung, Ho- Choi, Lars Olson, Barry J. J. Hoffer, Kuan-Yin Tseng
Summary: This study evaluated the efficacy of PT320 on L-DOPA-induced dyskinetic behaviors and neurochemistry in a progressive Parkinson's disease MitoPark mouse model. The results showed that early administration of PT320 significantly reduced the severity of L-DOPA-induced abnormal involuntary movements, particularly in excessive standing and abnormal paw movements. However, late administration of PT320 did not improve any L-DOPA-induced dyskinesia measurements. Furthermore, early treatment with PT320 increased both tonic and phasic release of dopamine in striatal slices, indicating its potential role in alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Chang-Qing Zheng, Hong-Xia Fan, Xiao-Xian Li, Jing-Jie Li, Shuo Sheng, Feng Zhang
Summary: Resveratrol (RES) has shown potential in alleviating dyskinesia associated with Parkinson's disease treatment, reducing the abnormal movements induced by L-DOPA while protecting DA neurons from long-term damage, and inhibiting neuroinflammatory reactions mediated by glial cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Chemistry, Medicinal
Victor A. D. Holanda, Julia J. Didonet, Manara B. B. Costa, Adriano H. do Nascimento Rangel, Edilson D. da Silva, Elaine C. Gavioli
Summary: This study explores the role of the neuropeptide S (NPS) and its receptor (NPSR) system in Parkinson's disease (PD), suggesting that the NPS/NPSR system may be an emerging therapeutic strategy for alleviating motor and non-motor dysfunctions of PD and possibly slowing disease progression.
Review
Neurosciences
Kai Yang, Xinyue Zhao, Changcai Wang, Cheng Zeng, Yan Luo, Taolei Sun
Summary: LID is a common issue in the treatment of Parkinson's disease, involving damage to multiple brain regions, with various theoretical models proposed to explain its mechanisms, necessitating a deeper understanding.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Clinical Neurology
Jillian J. Weeks, Anthony A. Grace, Alan F. Sved
Summary: The study showed that both acute and chronic administration of nicotine improved deficits in schizophrenia-like behaviors and normalized neuronal activity in specific brain regions in the schizophrenia rodent model. These findings support the self-medication hypothesis for smoking in schizophrenia and suggest the potential of nicotinic modulation in future pharmacotherapies.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Suresh Paudel, Xiao Min, Srijan Acharya, Daulat Bikram Khadka, Goon Yoon, Kyeong-Man Kim, Seung Hoon Cheon
BIOORGANIC & MEDICINAL CHEMISTRY
(2018)
Article
Neurosciences
Leandro Val Sayson, Chrislean Jun Botanas, Raly James Perez Custodio, Arvie Abiero, Mikyung Kim, Hyun Jun Lee, Hee Jin Kim, Sung Yeun Yoo, Kun Won Lee, Hye Won Ryu, Srijan Acharya, Kyeong-Man Kim, Yong Sup Lee, Jae Hoon Cheong
PSYCHOPHARMACOLOGY
(2019)
Article
Biochemistry & Molecular Biology
Srijan Acharya, Kyeong-Man Kim
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2019)
Article
Biochemistry & Molecular Biology
Mikyung Kim, Srijan Acharya, Chrislean Jun Botanas, Raly James Custodio, Hyun Jun Lee, Leandro Val Sayson, Arvie Abiero, Yong Soo Lee, Jae Hoon Cheong, Kyeong-man Kim, Hee Jin Kim
BIOMOLECULES & THERAPEUTICS
(2020)
Article
Pharmacology & Pharmacy
Xiao Min, Xiaohan Zhang, Ningning Sun, Srijan Acharya, Kyeong-Man Kim
BIOCHEMICAL PHARMACOLOGY
(2019)
Article
Biochemistry & Molecular Biology
Mei Zheng, Xiaohan Zhang, Ningning Sun, Xiao Min, Srijan Acharya, Kyeong-Man Kim
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2020)
Article
Biochemistry & Molecular Biology
Srijan Acharya, Dooti Kundu, Hyun Jin Choi, Kyeong-Man Kim
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
(2020)
Article
Pharmacology & Pharmacy
Srijan Acharya, Dooti Kundu, Kyeong-Man Kim
Summary: The endocytosis of alpha 4 beta 2 nicotinic ACh receptors occurs through clathrin-mediated endocytosis in a dynamin-dependent manner. Src-mediated phosphorylation of the nAChR alpha 4 subunit at Y575 by 14-3-3 eta is required for endocytosis, with assistance from beta-arrestin1 and GRK2. Endocytosis leads to ubiquitination and down-regulation of alpha 4 beta 2 nAChRs.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Suresh Paudel, Eunae Kim, Anlin Zhu, Srijan Acharya, Xiao Min, Seung Hoon Cheon, Kyeong-Man Kim
Summary: This study identified the diverse effects of synthetic 4-benzylpiperidine carboxamides on serotonin, norepinephrine, and dopamine reuptake, as well as the critical structural features contributing to the selectivity of these molecules for each of the monoamine transporters. Additionally, the study found that specific residues on the compounds bound to the transporters and highlighted the functional role of a dopamine reuptake inhibitor in regulating dopamine D-2 receptor function.
BIOMOLECULES & THERAPEUTICS
(2021)
Article
Neurosciences
Chrislean Jun Botanas, Raly James Perez Custodio, Hee Jin Kim, June Bryan de la Pena, Leandro Val Sayson, Darlene Mae Ortiz, Mikyung Kim, Hyun Jun Lee, Srijan Acharya, Kyeong-Man Kim, Cheol Jung Lee, Jong Hoon Ryu, Yong Sup Lee, Jae Hoon Cheong
Summary: The study reveals that both S-MXE and R-MXE exhibit antidepressant effects in mice, possibly mediated via glutamatergic and serotonergic mechanisms. R-MXE induces fewer behavioral side effects compared to S-MXE, making it a safer antidepressant option.
Article
Multidisciplinary Sciences
Orlandric Miree, Sanjeev Kumar Srivastava, Mohammad Aslam Khan, Fnu Sameeta, Srijan Acharya, Harrison Ndetan, Karan Pal Singh, Kate Louise Hertweck, Santanu Dasgupta, Luciana Madeira da Silva, Rodney Paul Rocconi, James Elliot Carter, Seema Singh, Ajay Pratap Singh
Summary: The study found that aberrant MYB expression in ovarian cancer is positively correlated with tumor grades and stages, and has race-specific prognostic value for African American patients, but not for Caucasian American patients. High levels of MYB transcripts in epithelial ovarian cancer subtypes are associated with poor survival in African American patients, highlighting MYB as a potentially useful clinical biomarker for prognosis in this population.
SCIENTIFIC REPORTS
(2021)
Article
Cell Biology
Sirin Saranyutanon, Srijan Acharya, Sachin Kumar Deshmukh, Mohammad Aslam Khan, Seema Singh, Ajay Pratap Singh
Summary: Nicotine induces M2 polarization of macrophages, enhancing their growth, motility, and invasion, potentially through the Src-STAT3 signaling axis. This novel role of nicotine in immunosuppression could be implicated in the pathogenesis of various diseases.
JOURNAL OF CELLULAR PHYSIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Srijan Acharya, Shashi Anand, Mohammad Aslam Khan, Haseeb Zubair, Sanjeev Kumar Srivastava, Seema Singh, Ajay Pratap Singh
Summary: MYB, a proto-oncogene, is overexpressed in prostate cancer and promotes its growth, aggressiveness, and resistance to androgen-deprivation therapy. Androgen signaling regulates MYB expression through transcriptional upregulation mediated by androgen receptor binding to the MYB promoter. High-dose androgen treatment leads to decreased MYB stability and induction of miR-150, which suppresses MYB expression and PCa cell growth.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Suresh Paudel, Xiao Min, Srijan Acharya, Daulat Bikram Khadka, Goo Yoon, Kyeong-Man Kim, Seung Hoon Cheon
BIOORGANIC & MEDICINAL CHEMISTRY
(2017)